# A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease

> **NCT02260674** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 114 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** JNJ-54861911, 10 milligram (mg)
- **DRUG:** JNJ-54861911, 50 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02260674
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02260674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02260674, "A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02260674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*